Bio-Techne (TECH) AI Stock Analysis

• Market Cap: $8.95B
• Dividend Yield: 0.56%
• Average Volume (3M): 1.92M
• Price to Earnings (P/E): 117.4
• Beta (1Y): 1.00
• Revenue Growth: 3.85%
• EPS Growth: -48.17%
• Country: US
• Employees: 3,100
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.42
• Shares Outstanding: 155,812,700
• 10 Day Avg. Volume: 1,952,361
• 30 Day Avg. Volume: 1,922,315
• PEG Ratio: -1.97
• Price to Book (P/B): 4.22
• Price to Sales (P/S): 6.64
• P/FCF Ratio: 31.59
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 7.35
• Enterprise Value/Gross Profit: 11.22
• Enterprise Value/Ebitda: 39.91
• 1Y Price Target: $67.38
• Price Target Upside: 18.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): 1.98
• Revenue Forecast (FY): $1.22B

• Rating: 64 Neutral
• Price Target: $70.00 ▲(22.83% Upside)

Bio-Techne's overall stock score is driven by stable financials with low leverage, positive technical momentum, and mixed earnings call insights. However, high valuation and declining revenue growth are significant concerns.

Positive Factors

Large Pharma Growth

The growth in revenue from large pharmaceutical customers indicates strong demand for Bio-Techne's products, which supports long-term revenue stability and expansion in a key market segment.

China Market Expansion

Continued growth in the Chinese market enhances Bio-Techne's global presence and taps into a rapidly expanding market, providing a durable growth opportunity.

Margin Expansion

The expansion of operating margins reflects improved operational efficiency, which can lead to sustained profitability and financial health over the long term.

Negative Factors

Organic Revenue Decline

A decline in organic revenue indicates challenges in maintaining growth momentum, which could affect future revenue stability and market competitiveness.

Biotech Funding Challenges

Persistent funding challenges in the biotech sector may limit Bio-Techne's growth opportunities and affect its ability to capitalize on emerging biotech innovations.

Protein Sciences Segment Decline

Declines in the Protein Sciences segment suggest potential issues in a core business area, which could impact overall revenue and market positioning if not addressed.

Bio-Techne Business Overview & Revenue Model

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Bio-Techne generates revenue through multiple key streams, primarily from the sale of its life science reagents and instruments. The Protein Sciences segment contributes significantly to the company's earnings by providing a variety of research and diagnostic products, including antibodies and proteins, which are essential in various research applications. The Diagnostics segment further enriches revenue through the sale of specialty reagents and assays used in clinical laboratories. Bio-Techne also benefits from strategic partnerships and collaborations with academic institutions, pharmaceutical companies, and research organizations, which often lead to co-development opportunities and expanded market reach. Additionally, the company may engage in licensing agreements for its proprietary technologies, further diversifying its income sources.

Bio-Techne Financial Statement Overview

Summary

Bio-Techne's financial performance is mixed. The income statement shows declining revenue and profit margins, while the balance sheet is stable with low leverage. Cash flow metrics indicate efficient cash management, but free cash flow growth has declined.

Income Statement

Bio-Techne's income statement shows a mixed performance. The TTM data indicates a decline in revenue growth rate by 23.8%, which is concerning. Gross profit margin remains strong at 65.37%, but the net profit margin has decreased to 6.41%, indicating reduced profitability. The EBIT and EBITDA margins have also declined, suggesting operational challenges. Overall, while the company maintains a solid gross profit margin, the declining revenue and profit margins are areas of concern.

Balance Sheet

The balance sheet of Bio-Techne reflects a stable financial position with a low debt-to-equity ratio of 0.19, indicating conservative leverage. The return on equity is modest at 3.60%, suggesting room for improvement in generating returns for shareholders. The equity ratio is healthy, showing a strong equity base relative to total assets. Overall, the balance sheet demonstrates financial stability with low leverage, but the return on equity could be enhanced.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 12.67% in the TTM period, which is a negative indicator. However, the operating cash flow to net income ratio is robust at 1.74, suggesting strong cash generation relative to net income. The free cash flow to net income ratio is also healthy at 0.89. Despite the decline in free cash flow growth, the company maintains solid cash flow ratios, indicating efficient cash management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.22B	1.22B	1.16B	1.14B	1.11B	931.03M
Gross Profit	797.45M	790.27M	769.73M	769.82M	756.50M	632.85M
EBITDA	224.19M	216.88M	313.14M	457.11M	413.76M	249.87M
Net Income	77.98M	73.40M	168.10M	285.26M	272.05M	140.41M
Balance Sheet
Total Assets	2.53B	2.56B	2.70B	2.64B	2.29B	2.26B
Cash, Cash Equivalents and Short-Term Investments	144.96M	162.19M	152.86M	204.31M	247.03M	231.55M
Total Debt	394.47M	444.06M	419.54M	454.96M	325.97M	420.55M
Total Liabilities	560.33M	639.06M	635.02M	672.18M	593.79M	691.72M
Stockholders Equity	1.97B	1.92B	2.07B	1.97B	1.70B	1.56B
Cash Flow
Free Cash Flow	224.06M	256.55M	236.10M	216.15M	280.36M	307.86M
Operating Cash Flow	251.25M	287.56M	298.98M	254.39M	325.27M	352.16M
Investing Cash Flow	-12.89M	-35.18M	-203.03M	-265.65M	-96.85M	-243.52M
Financing Cash Flow	-286.54M	-253.91M	-122.40M	22.62M	-242.85M	-62.55M

Bio-Techne Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 56.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 56.99 is below the 20-day moving average (MA) of 61.21, below the 50-day MA of 61.07, and above the 200-day MA of 55.24, indicating a neutral trend. The MACD of -0.75 indicates Positive momentum. The RSI at 38.14 is Neutral, neither overbought nor oversold. The STOCH value of 11.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.

Bio-Techne Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	76 Outperform	$8.53B	94.01	16.47%	―	17.92%	-26.13%
HALO	73 Outperform	$7.58B	13.82	124.50%	―	31.19%	59.01%
TECH	64 Neutral	$8.95B	117.42	3.80%	0.56%	3.85%	-48.17%
JAZZ	64 Neutral	$10.31B	-27.17	-9.06%	―	4.14%	-179.96%
RYTM	59 Neutral	$7.50B	-36.05	-240.36%	―	54.92%	28.47%
ROIV	58 Neutral	$15.95B	-41.08	-14.73%	―	-83.82%	-109.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Bio-Techne Corporate Events

Bio-Techne Reports Q1 2026 Revenue and EPS Growth

At its annual meeting, Bio-Techne Corporation announced the election of nine directors and the approval of executive compensation and KPMG LLP as its independent auditor for fiscal year ending June 30, 2026. The company reported a slight decrease in first-quarter fiscal 2026 revenue to $286.6 million, with a GAAP EPS increase to $0.24. The divestiture of Exosome Diagnostics and cost initiatives improved operating margins. Despite challenges in the emerging biotech sector, Bio-Techne saw stabilization in the US academic market and growth in its ProteinSimple and Spatial Biology segments. The company remains focused on its strategic growth pillars, including cell therapy, where some customers received FDA Fast Track Designation.